**Number 252, August 15, 2025**

Change to the Management of Zepbound® (tirzepatide) for MassHealth Patients with Diabetes and Overweight or Obesity Beginning October 1, 2025

Effective October 1, 2025, MassHealth is implementing a step therapy requirement for patients with both diabetes and overweight or obesity who are newly requesting Zepbound® (tirzepatide) treatment. Members with diabetes initiating treatment with Zepbound® (tirzepatide) will be required to step through Mounjaro® (tirzepatide) first or document medical necessity for use of Zepbound® (tirzepatide).

Members with approved prior authorizations for Zepbound® (tirzepatide) will be able to continue to receive Zepbound® (tirzepatide) until their currently approved prior authorization expires. Upon resubmission for continuation of therapy, members with both diabetes and overweight or obesity stable on Zepbound® (tirzepatide) will be required to transition to Mounjaro® (tirzepatide) as part of the prior authorization renewal process or document medical necessity for use of Zepbound® (tirzepatide).

Zepbound® (tirzepatide) and Mounjaro® (tirzepatide) contain the same active medication and are identical in dosing and administration frequency. Prior authorization criteria for Zepbound® (tirzepatide) and Mounjaro® (tirzepatide) can be found on the MassHealth Drug List.

The MassHealth Drug List is on the MassHealth Pharmacy Program website at [www.mass.gov/masshealth/pharmacy](https://www.mass.gov/masshealth/pharmacy).